New immunotherapy MK-1045 targets Hard-to-Treat lymphomas
NCT ID NCT07519772
First seen Apr 10, 2026 · Last updated May 06, 2026 · Updated 3 times
Summary
This early-phase trial tests MK-1045, an immunotherapy that helps the immune system fight cancer, in people with two types of non-Hodgkin lymphoma (follicular and diffuse large B-cell) that have not responded to at least two prior treatments. The study will enroll about 200 participants to evaluate safety and whether the cancer shrinks or disappears. It is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.